Multiple System Atrophy: Friends bare all in fundraising effort
Fridrik Thorsteinsson, who has MSA, is raising money to help others with the condition.
Source: bbc.co.uk
📰 Multiple System Atrophy News
Page 28 - Multiple System Atrophy News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Multiple System Atrophy. Real-time updates on events, politics, business and more.
Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to...
United States Comunidad Autonoma De Cataluna Miltonh Werner Warren Olanow Movement Disorders On Company Phase
Source: prnewswire.com
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...
United States San Francisco David Stamler National Institute Of Health Parkinson Foundation European Commission
Source: prnewswire.com
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
Colorectal impairment reversed in a preclinical model of Parkinson’s Disease ATH434 presents a novel mechanism of action for the treatment...
United States San Francisco David Stamler National Institute Of Health Parkinson Foundation European Commission
Source: fnarena.com
Appendix 4C - Q1 FY22 Quarterly Cash Flow Report
/PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease...
United States San Francisco Daniel Claassen David Stamler Prnewswire Alterity Therapeutics Limited Drug Administration
Source: prnewswire.com
Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course...
United States Milton Werner Inhibikase Therapeutics Inc Panel Discussion Michaelj Fox Foundation Alpha Synuclein Summit Prnewswire Inhibikase Therapeutics Inc
Source: prnewswire.com
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced an expansion of the...
Source: asiaone.com
Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course...
United States Milton Werner Company Phase Inhibikase Therapeutics Inc Inhibikase Therapeutics Abelson Tyrosine Kinase
Source: prnewswire.com
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...
Source: prnewswire.com